Trades at 34x forward PE, with 20% growth rate starting next year. Technicals are positive. Shares are above 200-day MA, which is trending higher. AWS growth is reaccelerating again. Automation is improving margins. Ads are high margin and boosting profitability. Prime membership is its ecosystem, and very powerful.
He sold on a negative technical formation, when shares started trading below a falling 200-day MA. Growth is weak, only 2-3%. Beer segment is really decelerating, as are wine/spirits. Premium names could suffer if consumers trade down in a weak economy. 35% acquisition of Canopy Growth may also be an overhang.
Some high-end names like Louis Vuitton have not been doing well. But TPR has been performing decently. Above 200-day MA, which is moving higher. Mid-high luxury, and that part of the market is doing better. Could be that the ultra-rich are "downshifting" into names owned by this brand.
15.5x forward PE, slightly above 10-year historical norms for this name. 9-10% growth. So valuation is decent. Investors should be cautious about impact of a downturn in the economy on this type of name.
Packaged treat business in general is challenged. Aside from tariffs, input costs are rising around the world due to normal inflation over the years. Growth rate's weaker than what he looks for. Only 3.3% earnings growth rate, though PE is cheap at 10x. Below 200-day MA, and moving lower. Value stocks can always get worse.
Showing 25 RSI, indicating oversold. Wait to see if it recovers. If he held it, he wouldn't 6-18 months from now. Nice yield of 4.5%, should be fairly safe.
Spike in stock is due to fears of an economic slowdown being put at bay. Theme parks are expanding, but will depend on macro environment. ESPN is more challenged. Disney+ is challenged because NFLX is beating everybody. Paying 20x PE for 12-13% growth. Doesn't dislike the name, but some segments are having a tough go.
Gold is becoming a crowded trade. Silver represents a more compelling opportunity. Currency-hedged access to physical silver in Canadian dollars. No foreign exchange risk. Silver just topped $35, a technical breakout; hasn't been there in over a decade. Industrial demand for silver. Mining supply for silver is pretty tight. Low correlation with stocks and bonds, so it helps lower portfolio risk. Bit of a hedge against an uncertain USD.
Gold/silver price right now is 90:1. Average over 50 years is 60:1. So silver is at a valuation discount right now. After the 2008 financial crisis, the gold/silver ratio was 80:1, and silver quadrupled after it hit that ratio.
SLV is the version to use if you have US dollars to spend.
Likes the reliable earnings. Steady prescriptions, specialty therapy (increases margins). In oncology drug space, which also has good margins. Automation and AI are helping margins further. 10-12% earnings growth rate at a decent PE. Just under 70% of Americans take at least 1 prescription drug a day; 25% take 4 or more. Population aging and more complex conditions will support volume growth of prescription drugs.
You don't find a chart better than this, long-term uptrend. Ascending channel of higher highs and higher lows. Yield is 0.39%.
Considers the US restrictions as short-term obstacles. Stock's starting to rebound quite nicely. The leader today in AI computing, and for the foreseeable future. Strong global thirst and demand for AI infrastructure. Unmatched advantages compared to other names in the space. Data centres are driving growth. Recent earnings beat.
AI adoption is still in very early stages. Still trading at 1x PEG ratio. Earnings growth is not reflected in the valuation. Sees EPS at 33% going forward. Yield is 0.03%.
Less exposed to financials than VDY, so you get more diversification.